Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/37564
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGürbüz, M.-
dc.contributor.authorAkkuş, E.-
dc.contributor.authorSakin, A.-
dc.contributor.authorUrvay, S.-
dc.contributor.authorDemiray, Atike Gökçen-
dc.contributor.authorŞahin, S.-
dc.contributor.authorŞakalar, T.-
dc.date.accessioned2021-02-02T09:27:05Z
dc.date.available2021-02-02T09:27:05Z
dc.date.issued2020-
dc.identifier.issn0300-8916-
dc.identifier.urihttps://hdl.handle.net/11499/37564-
dc.identifier.urihttps://doi.org/10.1177/0300891620969823-
dc.description.abstractPurpose: Taxane-containing combinations are recommended for the first-line therapy of advanced gastric cancer. It is not known which chemotherapy regimen is the best with trastuzumab for HER2-positive patients. The aim of this study was to compare taxane-containing intensified chemotherapy versus standard chemotherapy in combination with trastuzumab in the first-line treatment of HER2-positive advanced gastric adenocarcinoma. Methods: This study is a retrospective multicenter study of the Turkish Oncology Group. A total of 130 HER2-positive patients with inoperable locally advanced, recurrent, or metastatic gastric adenocarcinoma being given chemotherapy plus trastuzumab as the first-line treatment were included from 16 different oncology centers. Trastuzumab combination with intensified chemotherapy including taxane or standard chemotherapy was compared in terms of progression-free survival (PFS), overall survival (OS), and toxicity. Results: There were 108 patients in the standard and 22 patients in the intensified chemotherapy group. PFS of the standard and intensified group were 5.6 months (95% confidence interval [CI] 4.8–6.4) and 5.3 months (95% CI 2.6–8), respectively (p = 0.70). OS of the standard and intensified group were 11.1 months (95% CI 8.3–13.9) and 15.2 months (95% CI 12.7–17.7), respectively (p = 0.03). Repeated analysis excluding patients given any previous therapy revealed similar results. The intensified group had more fever and febrile neutropenia. Conclusion: Trastuzumab combination with intensified chemotherapy provides better OS in first-line treatment of HER2-positive advanced gastric cancer. Further large-scale studies should be performed in HER2-positive patients. © Fondazione IRCCS Istituto Nazionale dei Tumori 2020.en_US
dc.language.isoenen_US
dc.publisherSAGE Publications Ltden_US
dc.relation.ispartofTumorien_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChemotherapyen_US
dc.subjectgastric canceren_US
dc.subjectHER2en_US
dc.subjecttrastuzumaben_US
dc.titleCombination of trastuzumab and taxane-containing intensified chemotherapy in first-line treatment of HER2-positive advanced gastric canceren_US
dc.typeArticleen_US
dc.authorid0000-0003-4397-5468-
dc.identifier.doi10.1177/0300891620969823-
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.pmid33167790en_US
dc.identifier.scopus2-s2.0-85095844183en_US
dc.identifier.wosWOS:000680238700001en_US
dc.identifier.scopusqualityQ3-
dc.ownerPamukkale University-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeArticle-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
crisitem.author.dept14.02. Internal Medicine-
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection
Show simple item record



CORE Recommender

SCOPUSTM   
Citations

5
checked on Dec 21, 2024

WEB OF SCIENCETM
Citations

5
checked on Dec 19, 2024

Page view(s)

54
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.